# Cannabis Sales Are Rising as Alcohol Declines (Newsletter: April 9, 2026) > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-sales-tax-impact-alcohol-decline-2026/ > **Published:** 2026-04-09T13:37:48-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:26:34-04:00 > **Clinical Summary:** Explore the cannabis sales tax impact amid rising cannabis sales and declining alcohol consumption in 2026. Understand market and health trends. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyResearchIndustry Why This Matters Clinicians should monitor cannabis use trends among patients with neurodegenerative diseases, as emerging evidence suggests cannabinoids may offer neuroprotective benefits in conditions like Parkinson’s disease. As cannabis sales increase relative to alcohol consumption, patients may view cannabis as a safer alternative without understanding the current evidence gaps, underscoring the need for evidence-based counseling about efficacy and safety. Healthcare providers must stay informed about [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) and remain prepared to discuss both potential therapeutic applications and risks with patients considering cannabis for neurological conditions. Clinical Summary Recent market data indicate a significant shift in consumer substance use patterns, with cannabis sales rising while alcohol consumption declines, suggesting changing public perception of cannabis as a consumer product and potential therapeutic agent. This trend reflects growing acceptance of cannabis in both recreational and medical contexts, which may increase patient inquiries and self-medication attempts in clinical settings. The referenced research highlighting cannabinoid interventions for neurological conditions like Parkinson’s disease underscores the emerging evidence base that is likely driving some of this demand, though the gap between preliminary research and robust clinical efficacy data remains substantial. Clinicians should anticipate increased patient interest in [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) for neurological and other conditions, requiring familiarity with available evidence, local regulations, and appropriate counseling on efficacy, safety, and drug interactions. The rising prevalence of cannabis use also necessitates routine screening and documentation in clinical practice to assess for both therapeutic benefit and potential harms. Physicians should stay informed about emerging cannabinoid research while maintaining evidence-based prescribing standards and helping patients distinguish between promising preliminary findings and established clinical benefit. Dr. Caplan’s Take “What we’re seeing in the market data mirrors what I’m observing in my practice: patients are increasingly viewing cannabis as a legitimate therapeutic option rather than a recreational substance, and the neuroscience on cannabinoids in neurodegenerative disease is compelling enough that we can no longer afford to dismiss these compounds out of hand—but this shift in consumer behavior has far outpaced our clinical evidence base, which means I’m spending more time than ever having careful conversations about which patients might benefit, which formulations to consider, and how to monitor for efficacy and adverse effects.” Clinical Perspective As cannabis sales continue to rise while alcohol consumption declines, clinicians should be aware of shifting substance use patterns in their patient populations, particularly given emerging evidence suggesting potential neuroprotective effects of certain cannabinoids in neurodegenerative diseases like Parkinson’s. However, the evidence base remains preliminary and heterogeneous, with most studies conducted in preclinical or small clinical samples, and critical questions persist regarding optimal dosing, formulation, long-term safety, and effects on concurrent medications. The legal landscape continues to evolve rapidly across jurisdictions, creating variability in product quality, labeling accuracy, and access that complicates evidence-based counseling. Clinicians should consider screening patients for cannabis use during neurological and psychiatric assessments, remain cautious about recommending cannabis as a treatment without robust clinical trial data, and stay informed about their local regulations to guide informed discussions with patients about both the theoretical promise and substantial uncertainties surrounding 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/medical-illness/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Cannabis+sales+are+rising+as+alcohol+declines+%28Newsletter%3A+April+9%2C+2026%29+%40drcaplan&url=https%3A%2F%2Fwww.marijuanamoment.net%2Fcannabis-sales-are-rising-as-alcohol-declines-newsletter-april-9-2026%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.marijuanamoment.net%2Fcannabis-sales-are-rising-as-alcohol-declines-newsletter-april-9-2026%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Cannabis+sales+are+rising+as+alcohol+declines+%28Newsletter%3A+April+9%2C+2026%29+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.marijuanamoment.net%2Fcannabis-sales-are-rising-as-alcohol-declines-newsletter-april-9-2026%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.marijuanamoment.net/cannabis-sales-are-rising-as-alcohol-declines-newsletter-april-9-2026/](https://www.marijuanamoment.net/cannabis-sales-are-rising-as-alcohol-declines-newsletter-april-9-2026/) Further Reading Research Digest[Research Digest: 5 Recent Studies – March 25, 2026](https://cedclinic.com/real-time-long-term-effects-medical-marijuana-research/) Evidence Watch[Cannabis Products and Contaminant Detection: Critical Review of Regulatory Oversight and Analytical Methodologies.](https://cedclinic.com/cannabis-contaminant-testing-regulations-review/) Cannabis Policy Wire[MCRGC, LLC; Decision and Order](https://cedclinic.com/federal-cannabis-manufacturing-decision-mcrgc-llc/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Study Finds Cannabis Compounds May Help Reduce Fatty Liver Disease](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) Explore emerging research on [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) and their potential benefits for fatty liver disease. [Read Study](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) [Trump Reclassifies State-Licensed Medical Marijuana as a Less-Dangerous Drug in a Historic Shift](https://cedclinic.com/federal-medical-marijuana-reclassification-impact/) Learn about the historic federal reclassification of medical marijuana and its implications. [Learn More](https://cedclinic.com/federal-medical-marijuana-reclassification-impact/) [Former Boxer Derek Chisora Advocates for Medical Cannabis Access to Manage Chronic Pain](https://cedclinic.com/former-boxer-derek-chisora-advocates-for-medical-cannabis-access-to-manage-chronic-pain/) Discover how Derek Chisora supports medical cannabis for chronic pain management. [Explore Story](https://cedclinic.com/former-boxer-derek-chisora-advocates-for-medical-cannabis-access-to-manage-chronic-pain/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).